Thank you Elisa Martini for featuring the IVORY trial published in @natmed.nature.com in Nature Portfolio’s Nature CVR 🫀 Main paper: rdcu.be/eX8W3 Commentary: rdcu.be/eYyG6 @jch403.bsky.social @ziadmallat.bsky.social @18fdg.bsky.social @ivorytrial.bsky.social @mallatlab.bsky.social

Perspective on Treg modulation to treat cardiovascular disease: rdcu.be/eU9l3

Highlights on the paper here: rdcu.be/eYyG6

Read the paper here: rdcu.be/eX8W3

Thank you @danieljdrucker.bsky.social for highlighting our work. This may be a game changer! Nature Medicine: rdcu.be/eX8W3

Daniel Drucker@danieljdrucker.bsky.social · 8mo ago

After 6 weeks of Rx patients with ACSs, low-dose IL-2 safely increases Tregcell levels and reduces arterial inflammation. www.nature.com/articles/s41...

Merci à @inserm.fr de parler de nos travaux et de les mettre en valeur! Nature Medicine: rdcu.be/eX8W3

Inserm@inserm.fr · 8mo ago

Dans un essai clinique de phase 2, une équipe de l'Inserm montre l’efficacité d’un nouveau traitement pour réduire l'inflammation chronique ou résiduelle qui peut être observée après un syndrome coronaire aigu (SCA). Lire le communiqué : presse.inserm.fr/syndrome-cor...

Amazing work by @rouchelles.bsky.social & Co. Prions of this team! Nature Medicine: rdcu.be/eX8W3

@rouchelles.bsky.social · 8mo ago

Delighted to share that the results of the IVORY trial were published in Nature Medicine: rdcu.be/eX8W3 This marks a significant scientific milestone for the field and the translational journey of low-dose IL-2.

A landmark demonstration that promoting Tregs to restore immune tolerance may be a powerful strategy to limit the burden of cardiovascular disease. A huge milestone made possible by an extraordinary team effort! rdcu.be/eX8W3

PARCC@parcc-inserm.bsky.social · 8mo ago

Pr Z Mallat @PARCC and colleagues show that, in patients with acute coronary syndromes, low-dose IL-2 safely increases Treg cell levels and reduces arterial inflammation. Learn More: www.nature.com/articles/s41...